Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 46.53M 41.68M 38.33M 34.73M 64.93M 4.42B 66.14M 457M 184M 2.32B 175M 171M 7.33B P/E 2026 *
8.38x
P/E 2027 * -2.21x
Enterprise Value 46.53M 41.68M 38.33M 34.73M 64.93M 4.42B 66.14M 457M 184M 2.32B 175M 171M 7.33B EV / Sales 2026 *
1.33x
EV / Sales 2027 * -
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
Oct. 29 Top Premarket Decliners MT
Oct. 23 Actinium Pharmaceuticals, Inc. Highlights First-In-Human Phase 1 Study of Atnm-400 A Her3-Targeted Non-Psma Radiotherapy in Prostate Cancer At Esmo 2026 CI
Oct. 20 Actinium Pharmaceuticals, Inc. Unveils Atnm-400 Data At Eanm 2026 with First-In-Human Her3-Targeted Radiotherapy Approach Beyond Psma in Prostate Cancer CI
Oct. 20 Actinium Pharmaceuticals, Inc. Announces New Preclinical Results Demonstrating Broad Antitumor Potential Of ATNM-400 Across Non-Small Cell Lung Cancer, Colorectal Cancer And Ovarian Cancer Models CI
Oct. 16 Actinium Pharmaceuticals, Inc. Announces Oral and Poster Presentations Highlighting Preclinical Data Supporting ATNM-400'S Broad Potential CI
Oct. 16 Actinium Pharmaceuticals Appoints Sean Maenpaa as Senior Vice President, Business Development CI
Oct. 15 Actinium Pharmaceuticals, Inc. Announces Appointment of Matt David, M.D. as Principal Financial Officer CI
Oct. 15 Actinium Pharmaceuticals, Inc. Announces Oral Presentation with Early Results from First-In-Human Phase 1 Study of Atnm-400 in Metastatic Castration-Resistant Prostate Cancer CI
Oct. 15 Actinium Pharmaceuticals, Inc. Announces Appointment of Matt David, M.D. as Chief Financial Officer CI
Aug. 14 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
Aug. 14 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
Aug. 07 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Jun. 03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
1 day-3.27%
1 week-2.63%
1 month+32.14%
3 months+76.84%
6 months+33.33%
Current year+8.82%
1 week 1.35
Extreme 1.35
1.56
1 month 0.95
Extreme 0.95
1.66
Current year 0.74
Extreme 0.735101
1.66
1 year 0.74
Extreme 0.735101
1.72
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
51.6
Manager TitleAgeSince
Chief Executive Officer 61 2017-06-08
Director of Finance/CFO 49 2026-10-13
Chief Tech/Sci/R&D Officer 57 2026-05-31
Director TitleAgeSince
Director/Board Member 72 2007-12-31
Chairman 61 2013-09-30
Director/Board Member 69 2013-11-07
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/26 Free

Chief Financial Officer

500,000 1.5903%
9/3/26 Other

Chief Technology Officer

333,648 1.0634%
9/3/26 Other

Chief Technology Officer

403,868 1.2872%
Change 5-day change 1-year change 3-year change Capi.($)
-3.27%-2.63%+3.50%-73.48% 46.53M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.02%+6.52%+43.17%+168.14% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.99%+176.64%

Financials

2026 *2027 *
Net sales 35M 31.35M 28.83M 26.13M 48.83M 3.32B 49.75M 344M 138M 1.75B 131M 129M 5.51B -
Net income 5.91M 5.29M 4.87M 4.41M 8.25M 561M 8.4M 58.08M 23.31M 295M 22.19M 21.71M 931M -30.95M -27.72M -25.49M -23.1M -43.18M -2.94B -43.99M -304M -122M -1.55B -116M -114M -4.87B
Net Debt - -
Projected Income Statement - Annual - Actinium Pharmaceuticals, Inc.
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
26-10-30 $1.480 -3.27% 157,720
26-10-29 $1.530 +10.87% 181,670
26-10-28 $1.380 -2.82% 56,557
26-10-27 $1.420 +1.43% 106,953
26-10-26 $1.400 -7.89% 205,864
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Actinium Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.480USD
Average target price
4.000USD
Spread / Average Target
+170.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Actinium Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ATNM Stock